Fibromyalgia - Pipeline Review, H2 2011
Global Markets Direct’s, 'Fibromyalgia - Pipeline Review, H2 2011', provides an overview of the Fibromyalgia therapeutic pipeline. This report provides information on the therapeutic development for Fibromyalgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fibromyalgia. 'Fibromyalgia - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Fibromyalgia.
- A review of the Fibromyalgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fibromyalgia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Fibromyalgia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage
Fibromyalgia – Pipeline Review, H2 2011 Fibromyalgia - Pipeline Review, H2 2011 Reference Code: GMDHC1350IDB Publication Date: September 2011 Fibromyalgia – Pipeline Review, H2 2011 GMDHC1350IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Fibromyalgia – Pipeline Review, H2 2011 Ta b le o f Co n te n ts Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Fibromyalgia Overview 8 Therapeutics Development 9 An Overview of Pipeline Products for Fibromyalgia 9 Fibromyalgia Therapeutics under Development by Companies 11 Fibromyalgia Therapeutics under Investigation by Universities/Institutes 13 Late Stage Products 15 Comparative Analysis 15 Mid Clinical Stage Products 16 Comparative Analysis 16 Early Clinical Stage Products 17 Comparative Analysis 17 Discovery and Pre-Clinical Stage Products 18 Comparative Analysis 18 Fibromyalgia Therapeutics - Products under Development by Companies 19 Fibromyalgia Therapeutics - Products under Investigation by Universities/Institutes 20 Companies Involved in Fibromyalgia Therapeutics Development 21 Meiji Holdings Co., Ltd. 21 Pfizer Inc. 21 Jazz Pharmaceuticals, Inc. 22 Chelsea Therapeutics, Inc. 22 e-Therapeutics plc 23 Concert Pharmaceuticals, Inc. 23 Adeona Pharmaceuticals, Inc. 24 SWITCH Biotech LLC 24 Fibromyalgia - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 JZP-6 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Lyrica - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Northera - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Fibromyalgia – Pipeline Review, H2 2011 GMDHC1350IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Fibromyalgia – Pipeline Review, H2 2011 Effirma - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Neurotropin - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ETS6218 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Droxidopa + Carbidopa - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 SWT06101 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Nuvigil - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Lidocaine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Gabapentin - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Fluoxetine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Mestinon - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Minalcipran - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Reflex - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Fibromyalgia – Pipeline Review, H2 2011 GMDHC1350IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3) Fibromyalgia – Pipeline Review, H2 2011 TNX-102 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 C-10291 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 THA902 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Fibromyalgia Therapeutics – Drug Profile Updates 51 Fibromyalgia Therapeutics - Discontinued Products 55 Fibromyalgia - Featured News 56 Sep 07, 2011: TONIX Pharmaceuticals’s Bedtime Very Low Dose Cyclobenzaprine Study Featured In Journal Of Rheumatology 56 Sep 06, 2011: Chelsea Therapeutics Receives New Patent For Use Of Droxidopa In Fibromyalgia 57 Aug 08, 2011: Chelsea Therapeutics Achieves Target Enrollment In Phase II Trial Of Droxidopa In Fibromyalgia 57 Jul 24, 2011: Neurim Announces Positive Results From Phase I And Phase Ib Clinical Trials With Neu-P11 58 Jul 05, 2011: Pfizer Announces Positive Top-Line Results Of Lyrica From Phase III Study Of Patients With Fibromyalgia In Japan 59 Jun 16, 2011: TONIX Pharmaceuticals Presents Promising Findings On Effects Of Very Low Dose Cyclobenzaprine In Patients With Fibromyalgia Syndrome 59 Nov 09, 2010: TONIX Pharmaceuticals Reports Analysis Of Phase IIa Study Of Very Low Dosage Cyclobenzaprine In Fibromyalgia Syndrome (FMS) 60 Oct 11, 2010: Jazz Receives FDA Complete Response Letter For JZP-6 For Treatment Of Fibromyalgia 61 Aug 20, 2010: Jazz Pharmaceuticals Provides Update On FDA Advisory Committee Meeting For JZP-6 In Fibromyalgia 61 Jul 01, 2010: Chelsea Reports Positive Interim Analysis Of Phase II Trial Of Droxidopa In Fibromyalgia 61 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 64 Contact Us 64 Disclaimer 64 Fibromyalgia – Pipeline Review, H2 2011 GMDHC1350IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(4) Fibromyalgia – Pipeline Review, H2 2011 Lis t o f Ta b le s Number of Products Under Development for Fibromyalgia, H2 2011
Pages to are hidden for
"Fibromyalgia - Pipeline Review, H2 2011"Please download to view full document